Australia's most trusted
source of pharma news
Friday, 21 November 2025
Posted 21 November 2025 AM
Telix has released trial results that could lead to more precision treatment in kidney cancer with its investigational PET imaging agent altering treatment decisions for nearly half of patients with unclear kidney masses.
The ZIRCON-X post-hoc study used imaging data from the Phase 3 ZIRCON study, which assessed the impact of TLX250-CDx imaging on clinical decision-making versus standard of care in 294 patients with indeterminate renal masses (IRMs).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.